|801-2, Jindong Mansion, No. 536 Xueshi Road, Yinzhou, Ningbo 315100, P.R.Chinaemail@example.com|
|Place of Origin:||China|
|Model Number:||PFS, 0.2ml/20 mg, 0.4ml/40 mg, 0.6ml/60 mg & 0.8ml/80 mg|
|Minimum Order Quantity:||10000boxes|
|Payment Terms:||L/C, T/T|
|Supply Ability:||20, 000 boxes per day|
|Product:||Enoxaparin Sodium Injection Pre-filled Syringe||Specification:||PFS, 0.2ml/20 Mg, 0.4ml/40 Mg, 0.6ml/60 Mg & 0.8ml/80 Mg|
|Standard:||In - House, BP||Packing:||2’s/box|
anti cancer drugs
Enoxaparin Sodium Injection Heparin And Low Molecular Weight Heparin Pre-filled injection
Product : Enoxaparin Sodium Injection Pre-filled Syringe
Specification : PFS, 0.2ml/20 mg, 0.4ml/40 mg, 0.6ml/60 mg & 0.8ml/80 mg
Standard : In - house, BP
Packing : 2’s/box
Enoxaparin is a low molecular weight heparin. Enoxaparin is used to prevent and treat deep vein thrombosis or pulmonary embolism, and is given as a subcutaneous injection. Enoxaparin binds to and accelerates the activity of antithrombin III. By activating antithrombin III, enoxaparin preferentially potentiates the inhibition of coagulation factors Xa and IIa. Factor Xa catalyzes the conversion of prothrombin to thrombin, so enoxaparin’s inhibition of this process results in decreased thrombin and ultimately the prevention of fibrin clot formation. Low molecular weight heparins are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin.
Indications and Dosages :
➤➤To prevent deep vein thrombosis (DVT) after hip or knee replacement and for continued prophylaxis after hospitalization for hip replacement
Adults. 30 mg every 12 hr, starting 12 to 24 hr after surgery for up to 14 days. Or, 40 mg daily, starting 9 to 15 hr after hip replacement surgery. Prophylaxis: 40 mg daily for 3 wk.
➤➤To prevent DVT after abdominal surgery for patients with thromboembolic risk factors (over age 40, obesity, general anesthesia lasting longer than 30 minutes, cancer, or a history of DVT or pulmonary embolism)
Adults. 40 mg daily, starting 2 hr before surgery and lasting 7 to 10 days.
➤➤To prevent ischemic complications of unstable angina and non–Q-wave MI
Adults. 1 mg/kg every 12 hr with 100 to 325 mg of aspirin daily for 2 to 8 days or until condition is stable.
dosage adjustment Dosage reduced to 30 mg daily if creatinine clearance is less than 30 ml/min/1.73 m2 and patient is receiving drug as prophylaxis in abdominal, hip, or knee replacement surgery or is acutely ill. Reduced to 1 mg/kg daily if creatinine clearance is less than 30 ml/ min/1.73 m2 and drug is given with aspirin to prevent ischemic complications of unstable angina and non–Q-wave MI, with warfarin as inpatient treatment for acute DVT with or without pulmonary embolism, or with warfarin as outpatient treatment of acute DVT without pulmonary embolism.
➤➤To treat acute ST-segment–elevation MI (STEMI)
i.v. injection, then subcutaneous injection
Adults. 30 mg I.V. as a single dose, followed by 1 mg/kg subcutaneously (maximum, 100 mg for first two doses). Then, 1 mg/kg subcutaneously every 12 hr.
dosage adjustment If patient also receives a thrombolytic, enoxaparin should be given 15 to 30 min before and 30 min after fibrinolytic therapy starts. If patient has percutaneous coronary intervention, give 0.3-mg/kg I.V. bolus if last enoxaparin dose was given more than 8 hr before balloon inflation.
Route Onset Peak Duration
SubQ Unknown 3–5 hr Up to 24 hr
Enoxaparin is a highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from 3800 to 5000 daltons. Enoxaparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Enoxaparin is a well known and commonly used anticoagulant which has antithrombotic properties. Enoxaparin inhibits reactions that lead to the clotting of blood and the formation of fibrin clots both in vitro and in vivo. Enoxaparin acts at multiple sites in the normal coagulation system. Small amounts of enoxaparin in combination with antithrombin III (enoxaparin cofactor) can inhibit thrombosis by inactivating activated Factor X and inhibiting the conversion of prothrombin to thrombin. Once active thrombosis has developed, larger amounts of enoxaparin can inhibit further coagulation by inactivating thrombin and preventing the conversion of fibrinogen to fibrin. Enoxaparin also prevents the formation of a stable fibrin clot by inhibiting the activation of the fibrin stabilizing factor. Its use should be avoided in patients with a creatinine clearance less than 20mL/min. In these patients, unfractionated heparin should only be used. As for monitoring, active partial thromboplastin time (aPTT) will only increase at high doses of low molecular weight heparins (LMWH). Therefore, monitoring aPTT is not recommended. However, anti-Xa activity can be measured to monitor the efficacy of the LMWH.
Mechanism of action :
The mechanism of action of enoxaparin is antithrombin-dependent. It acts mainly by accelerating the rate of the neutralization of certain activated coagulation factors by antithrombin, but other mechanisms may also be involved. The antithrombotic effect of enoxaparin is well correlated to the inhibition of factor Xa. Enoxaparin interacts with Antithrombin III, Prothrombin and Factor X. Enoxaparin binds to and accelerates the activity of antithrombin III. By activating antithrombin III, enoxaparin preferentially potentiates the inhibition of coagulation factors Xa and IIa.
Contact Person: Luke Liu